Utility of cenegermin for the management of neurotrophic keratopathy after penetrating keratoplasty
BACKGROUND: The study aimed to report the outcomes of patients treated with cenegermin 0.002% for neurotrophic keratopathy (NK) following penetrating keratoplasty (PK). MATERIALS AND METHODS: This retrospective case series included patients evaluated at a tertiary care hospital who completed an 8-we...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-05-01
|
| Series: | Oman Journal of Ophthalmology |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ojo.ojo_311_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850080962566684672 |
|---|---|
| author | Alexandra R. Zaloga Ashley Khalili Brandon D. Ayres Brenton D. Finklea Beeran B. Meghpara Christopher J. Rapuano Zeba A. Syed |
| author_facet | Alexandra R. Zaloga Ashley Khalili Brandon D. Ayres Brenton D. Finklea Beeran B. Meghpara Christopher J. Rapuano Zeba A. Syed |
| author_sort | Alexandra R. Zaloga |
| collection | DOAJ |
| description | BACKGROUND:
The study aimed to report the outcomes of patients treated with cenegermin 0.002% for neurotrophic keratopathy (NK) following penetrating keratoplasty (PK).
MATERIALS AND METHODS:
This retrospective case series included patients evaluated at a tertiary care hospital who completed an 8-week course of cenegermin for NK within 12 months following PK. The primary outcome measure was NK stage, while secondary outcomes included complete epithelial healing, epithelial defect size, and best-corrected visual acuity (BCVA) at baseline and four time points during and following treatment. We also evaluated disease progression.
RESULTS:
Fourteen eyes of 14 patients were included and demonstrated significant improvement in NK stage at 4 weeks (1.1 ± 0.7; P = 0.006) and 8 weeks after treatment initiation (0.9 ± 0.7; P = 0.002) and 1 month (0.6 ± 0.5; P < 0.001) and 6 months after treatment completion (0.8 ± 0.9; P = 0.002) compared to baseline (1.6 ± 0.5). Complete epithelial healing was noted 1 month (42.9%; P = 0.016) and 6 months after treatment completion (38.5%; P = 0.016). Epithelial defect size improved to <5 mm2 at all points (P < 0.05) during and after treatment compared to baseline (37.24 mm2). Improvement in BCVA was not significant at any time point. Two (14.3%) patients experienced disease progression up to 6 months of follow-up.
CONCLUSIONS:
Following an 8-week course of cenegermin, patients with a history of PK demonstrated improvement in NK stage, epithelial healing, and reduced epithelial defect size lasting 6 months after treatment completion. Patients with prior PK and NK may be considered candidates for cenegermin treatment. |
| format | Article |
| id | doaj-art-6ddb2991e73449228716fcff60654f96 |
| institution | DOAJ |
| issn | 0974-620X 0974-7842 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Oman Journal of Ophthalmology |
| spelling | doaj-art-6ddb2991e73449228716fcff60654f962025-08-20T02:44:50ZengWolters Kluwer Medknow PublicationsOman Journal of Ophthalmology0974-620X0974-78422025-05-0118219820410.4103/ojo.ojo_311_24Utility of cenegermin for the management of neurotrophic keratopathy after penetrating keratoplastyAlexandra R. ZalogaAshley KhaliliBrandon D. AyresBrenton D. FinkleaBeeran B. MeghparaChristopher J. RapuanoZeba A. SyedBACKGROUND: The study aimed to report the outcomes of patients treated with cenegermin 0.002% for neurotrophic keratopathy (NK) following penetrating keratoplasty (PK). MATERIALS AND METHODS: This retrospective case series included patients evaluated at a tertiary care hospital who completed an 8-week course of cenegermin for NK within 12 months following PK. The primary outcome measure was NK stage, while secondary outcomes included complete epithelial healing, epithelial defect size, and best-corrected visual acuity (BCVA) at baseline and four time points during and following treatment. We also evaluated disease progression. RESULTS: Fourteen eyes of 14 patients were included and demonstrated significant improvement in NK stage at 4 weeks (1.1 ± 0.7; P = 0.006) and 8 weeks after treatment initiation (0.9 ± 0.7; P = 0.002) and 1 month (0.6 ± 0.5; P < 0.001) and 6 months after treatment completion (0.8 ± 0.9; P = 0.002) compared to baseline (1.6 ± 0.5). Complete epithelial healing was noted 1 month (42.9%; P = 0.016) and 6 months after treatment completion (38.5%; P = 0.016). Epithelial defect size improved to <5 mm2 at all points (P < 0.05) during and after treatment compared to baseline (37.24 mm2). Improvement in BCVA was not significant at any time point. Two (14.3%) patients experienced disease progression up to 6 months of follow-up. CONCLUSIONS: Following an 8-week course of cenegermin, patients with a history of PK demonstrated improvement in NK stage, epithelial healing, and reduced epithelial defect size lasting 6 months after treatment completion. Patients with prior PK and NK may be considered candidates for cenegermin treatment.https://journals.lww.com/10.4103/ojo.ojo_311_24cenegerminneurotrophic keratopathypenetrating keratoplasty |
| spellingShingle | Alexandra R. Zaloga Ashley Khalili Brandon D. Ayres Brenton D. Finklea Beeran B. Meghpara Christopher J. Rapuano Zeba A. Syed Utility of cenegermin for the management of neurotrophic keratopathy after penetrating keratoplasty Oman Journal of Ophthalmology cenegermin neurotrophic keratopathy penetrating keratoplasty |
| title | Utility of cenegermin for the management of neurotrophic keratopathy after penetrating keratoplasty |
| title_full | Utility of cenegermin for the management of neurotrophic keratopathy after penetrating keratoplasty |
| title_fullStr | Utility of cenegermin for the management of neurotrophic keratopathy after penetrating keratoplasty |
| title_full_unstemmed | Utility of cenegermin for the management of neurotrophic keratopathy after penetrating keratoplasty |
| title_short | Utility of cenegermin for the management of neurotrophic keratopathy after penetrating keratoplasty |
| title_sort | utility of cenegermin for the management of neurotrophic keratopathy after penetrating keratoplasty |
| topic | cenegermin neurotrophic keratopathy penetrating keratoplasty |
| url | https://journals.lww.com/10.4103/ojo.ojo_311_24 |
| work_keys_str_mv | AT alexandrarzaloga utilityofcenegerminforthemanagementofneurotrophickeratopathyafterpenetratingkeratoplasty AT ashleykhalili utilityofcenegerminforthemanagementofneurotrophickeratopathyafterpenetratingkeratoplasty AT brandondayres utilityofcenegerminforthemanagementofneurotrophickeratopathyafterpenetratingkeratoplasty AT brentondfinklea utilityofcenegerminforthemanagementofneurotrophickeratopathyafterpenetratingkeratoplasty AT beeranbmeghpara utilityofcenegerminforthemanagementofneurotrophickeratopathyafterpenetratingkeratoplasty AT christopherjrapuano utilityofcenegerminforthemanagementofneurotrophickeratopathyafterpenetratingkeratoplasty AT zebaasyed utilityofcenegerminforthemanagementofneurotrophickeratopathyafterpenetratingkeratoplasty |